Revvity Nears 52-Week High, but This Analyst Thinks Stock Can Climb Another 20%

10/6/2026
Impact: 75
Healthcare

Revvity Inc. (NYSE: RVTY) received an Outperform rating from William Blair, which anticipates over 20% upside for the stock as improving life sciences markets and AI integration could drive revenue growth. The company reported second-quarter adjusted earnings of $1.41 per share and sales of $729.67 million, both exceeding estimates, and raised its fiscal 2026 earnings guidance to $5.30-$5.40 per share. Revvity's shares were down 2.04% at $154.15, nearing its 52-week high of $158.28.

AI summary, not financial advice

Share: